Biotricity, Inc. - Common Stock (BTCY)
0.4631
0.00 (0.00%)
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
Biotricity just reported results for the first quarter of 2025.
Via InvestorPlace · August 20, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
BTCY stock results show that Biotricity beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024.
Via InvestorPlace · June 27, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · February 14, 2024
![](https://cdn.benzinga.com/files/images/story/2023/07/05/btcy.png?width=1200&height=800&fit=crop)
H.C.
Via Benzinga · July 5, 2023
![](https://cdn.benzinga.com/files/images/story/2024/04/15/image20.jpeg?width=1200&height=800&fit=crop)
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQRARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
Via Benzinga · April 15, 2024
![](https://investorplace.com/wp-content/uploads/2021/04/wall-street-federal-hall.jpg)
It's time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning.
Via InvestorPlace · November 7, 2023
![](https://cdn.benzinga.com/files/images/story/2024/02/20/fluor_-_logo.jpg?width=1200&height=800&fit=crop)
Shares of Fluor Corporation (NYSEFLR) fell during Tuesday’s session following fourth-quarter results.
Via Benzinga · February 20, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · October 30, 2023
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · October 27, 2023
![](https://cdn.benzinga.com/files/images/story/2023/earnings_image.jpeg?width=1200&height=800&fit=crop)
Companies Reporting Before The Bell • Barclays (NYSEBCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion.
Via Benzinga · February 20, 2024
![](https://cdn.benzinga.com/files/images/story/2023/10/27/image30.jpeg?width=1200&height=800&fit=crop)
Gainers Apollomics, Inc. (NASDAQAPLM) shares surged 88.4% to $1.07 stoma multiforme with PTPRZ-MET fusion.
Via Benzinga · October 27, 2023
![](https://cdn.benzinga.com/files/images/story/2023/07/25/screenshot_2023-07-25_at_9.01.17_pm.png?width=1200&height=800&fit=crop)
The integration of AI technology in healthcare has revolutionized the industry, particularly in the areas of automation, big data analytics, and optimization. AI-powered software is designed to assist healthcare workers by performing tasks that are time-consuming and require high levels of accuracy.
Via Benzinga · July 25, 2023
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · July 25, 2023
![](https://cdn.benzinga.com/files/images/story/2023/07/05/image20.jpg?width=1200&height=800&fit=crop)
Gainers Allarity Therapeutics, Inc. (NASDAQALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in DRP-selected metastatic breast cancer patients.
Via Benzinga · July 5, 2023
![](https://cdn.benzinga.com/files/images/story/2023/06/30/nike_-_logo.jpg?width=1200&height=800&fit=crop)
With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows:
Via Benzinga · June 30, 2023
![](https://cdn.benzinga.com/files/images/story/2023/06/30/image17.jpg?width=1200&height=800&fit=crop)
The CNN Money Fear and Greed index showed further increase in overall sentiment among U.S. investors on Thursday.
Via Benzinga · June 30, 2023
![](https://public.newsdirect.com/355498666/snsiTDYq.jpg)
FDA Issues Warning Letter To iRhythm: An Opportunity For The Cardiac Monitoring Space And One Company In Particular?
Via News Direct · June 21, 2023
![](https://cdn.benzinga.com/files/images/story/2023/06/20/screenshot_2023-06-20_at_5.26.39_pm.png?width=1200&height=800&fit=crop)
The Food and Drug Administration (FDA) has issued a warning to the heart monitoring company iRhythm (NASDAQIRTC), stating that its products include viol
Via Benzinga · June 20, 2023